In this study, we did a bioassay employing mice with a dominant-negative p53 mutation (p53 Val135/WT ) to assess whether a germ-line p53 mutation predisposed mice toward the development of squamous cell carcinomas (SCC) in the oral cavity. Treatment of the mouse oral cavity with 4-nitroquinoline-1-oxide produced a 66%, 91%, and 20% tumor incidence in the oral cavity, esophagus, and forestomach/stomach, respectively, in p53
Introduction
Head and neck cancer accounts for 3% to 5% of all malignancies in Western countries, with cancer of the oral cavity accounting for 30% of all head and neck cancers. Squamous cell carcinoma (SCC) of the oral cavity is the sixth most frequent cancer in the world and f30,000 new cases are diagnosed annually in the United States (1) . The development of oral SCC shows a positive correlation with exposure to tobacco and alcohol. Multiple genetic changes are thought to contribute to the development of SCCs of oral cavity (2) (3) (4) (5) .
The molecular pathways involved in the development of oral SCC are poorly understood. Mutations in the p53 gene are the most prevalent mutations in human cancer and can be sporadic or germ-line in nature (6, 7) . The p53 protein is present in normal cells and induces cell cycle arrest or apoptosis in the presence of DNA damage. Mutant p53 protein lacks this property. Germ-line mutations in p53 are associated with the Li-Fraumeni family cancer syndrome, which predisposes individuals to multiple, unpredictable, aggressive, and often lethal tumors (8) . We have shown previously that p53 transgenic mice with a dominant-negative p53 mutation are highly susceptible to carcinogen-induced lung adenoma/adenocarcinoma, uterine sarcoma, and colon adenocarcinoma (9) (10) (11) (12) . Mutation in the p53 gene is also commonly seen in SCCs of oral mucosa (13) (14) (15) (16) . Abnormal staining of p53 protein is a frequent finding (17) (18) (19) .
The objective of this study was to determine the role of p53 tumor suppressor in mouse oral SCC development. A bioassay using dominant-negative p53 transgenic (p53 Val135/WT ) mice was done to assess if there is a correlation between germ-line p53 mutation and susceptibility toward SCC in the oral cavity. Treatment of mouse oral epithelia with 4-nitroquinoline-1-oxide (4NQO) is a well-established model for human head and neck SCCs (20, 21) . The developing tumors are moderate to welldifferentiated SCCs that morphologically resemble human tumors (19) . We found that p53 transgenic mice are highly susceptible to 4NQO-induced oral cancer and that the resulting tumors are more likely to progress. In addition, we examined that the molecular pathways involved in the tumor development include apoptosis and cell cycle arrest.
Results

Effect of p53 Germ-line Mutation (Ala 135
Val) on 4NQO-Induced Tumorigenesis
To determine whether the p53 Val135/WT mice would be more susceptible to chemical induction of upper gastrointestinal tumors than wild-type littermates, a 4NQO-induced tumor bioassay was conducted. Six-week-old p53
Val135/WT and p53
WT/WT mice were treated with 4NQO. After 16 weeks of treatment and 32 weeks postinitiation, p53 Val135/WT mice had developed significantly more and larger upper gastrointestinal tumors, including oral cavity, esophagus, and forestomach/ stomach tumors, than their p53 WT/WT counterparts. As shown in Table 1 and Fig. 1A , in 4NQO-treated groups, the survival rate of wild-type mice was significantly higher than the p53 transgenic mice. Most p53
Val135/WT mice were either dead or moribund before the end of the experiment due to advanced oral/upper gastrointestinal tumors. All tumor phenotypes, including those from the mice either dead or moribund, were included in Table 1 . As shown in Table 1,  treatment of p53 Val135/WT mice with 4NQO produced more than 66%, 91%, and 20% incidences of oral mucosa, esophagus, and forestomach/stomach tumors, respectively, whereas only 25%, 58%, and 4% tumor incidences were observed in the oral mucosa, esophagus, and forestomach/ stomach, respectively, in wild-type mice treated with the same carcinogen (Table 1) . 4NQO produced an average of f0.3 tongue SCC and f1.0 esophageal SCC in p53 WT/WT mice, whereas treatment of p53
Val135/WT mice produced an average of f1.0 tongue SCC and f3.2 esophageal SCC (Table 1) .
Morphologically, oral cavity lesions included lip, tongue, palate, and larynx tumors. Some tumors were grossly enlarged with invasion to surrounding tissues. In some advanced cases in the p53
Val135/WT group, the entire oral cavity was diffusely swollen and the bottom of the oral cavity was grossly enlarged, with head and neck lymph node involvement. Sometimes, enlarged oral SCC could be easily palpated through the neck or protruded through the mouth. Histopathologically, these tumors were oral cavity, esophageal, and forestomach SCCs (Fig. 1B) . Most SCCs showed proliferation into the submucosa and exhibited features of squamous cell differentiation, such as keratin pearls. The majority of p53
Val135/WT mice developed tumors more rapidly than the wild-type mice and the tumors displayed more obvious features of malignancy, including large size, lymph node involvement, more nuclear atypia, and invasiveness. Furthermore, histopathology data showed that SCCs had relatively poorly differentiated cells in p53 Val135/WT mice were terminated before the end of the experiment due to overt SCCs. The survivorship data are shown in Fig. 1A .
Microarray Analysis of Normal and Tumor Tissues from Tongues Treated with 4NQO
To identify the precise genes or pathways responsible for these differences in tumor susceptibility and growth, four to five normal and tumor samples from both p53
WT/WT and p53
Val135/WT groups were examined. In normal tongue tissues, microarray analysis revealed 271 genes differentially expressed between p53
WT/WT and p53 Val135/WT mice treated with 4NQO. Among them, 67 genes were underexpressed, whereas 204 genes were overexpressed in p53
Val135/WT normal tissues when using 2-fold change and P < 0.05 (t test) as cutoff ( Fig. 2A) . Moreover, when we compared the expression of tongue SCCs, 913 genes were found, which showed differential expression between p53
WT/WT and p53 Val135/WT tumors. Among them, 377 genes were underexpressed, whereas 536 genes were overexpressed in p53
Val135/WT tumors ( Table 2 ; Fig. 2B ). We also ranked the genes in the normal-to-normal and tumor-to-tumor comparisons based on fold expression difference in Tables 3  and 4 . We then verified the finding from microarray analysis that the expression of Rassf1A was decreased in tumors from p53
Val135/WT mice when compared with those from p53
WT/WT mice. We conducted methylation-specific PCR (MSP) analysis to obtain a methylation profile of Rassf1A in SCC. As shown in Fig. 3 , 25% of tumors from p53 WT/WT mice and 75% of the tumors from p53
Val135/WT mice showed Rassf1A promoter methylation. No Rassf1A methylation was detected in paired normal tissues. These results indicate a correlation between array data and hypermethylation status of the Rassf1A gene in SCC (Table 2) .
Finally, we used GenMAPP to illustrate all the available pathways containing differentially expressed genes associated with p53 status in tongue tumorigenesis. Several cellular pathways, such as apoptosis, cell cycle, transforming growth factor-h, and Ras-mitogen-activated protein kinase pathways, showed alterations in both 4NQO-treated normal tissue and WT/WT versus p53 Val135/WT mice. Among them, the cell cycle and apoptotic signaling pathways played an important role in 4NQO-induced tongue tumorigenesis. As shown in the cell cycle regulation pathway (Fig. 4A ), the expression of p53, Atm, Bub1, Tgfb1, Cdc25b, Orc21, and Cdc7 was differentially expressed in normal tissues of p53 WT/WT versus p53 Val135/WT mice. In addition, the expression Mdm2, Ccna1, Abl1, and Tfdp1 was differentially expressed in tumors of p53 WT/WT versus p53 Val135/WT mice. In the apoptotic pathways, expression of Bid and p53 was altered in normal tissues of the p53
Val135/WT mice, whereas several death receptors or activators of cell death, such as Tnf, Tnfsf10, Prf1, Tradd, Ripk1, Apaf1, Mdm2, Bcl2, and Casp7, were found altered in p53
Val135/WT tumors (Fig. 4B ). These results indicate that deregulation of cell cycle and reduction of apoptosis activity may, in part, contribute to the increased oral malignancy in p53
Val135/WT mice on carcinogen exposure.
Discussion
In the present study, we induced upper gastrointestinal malignancy with the carcinogen 4NQO, which was documented to induce oral cavity tumors in various species and multiple strains of mice (20) (21) (22) . Using p53 transgenic mice, we found that introduction of a dominant-negative p53 mutant (Ala 135 Val) into the germ-line significantly enhanced tumorigenesis in the oral mucosa and upper gastrointestinal system on 4NQO treatment. The most striking distinction between p53
Val135/WT and p53 WT/WT mice on carcinogen treatment was that the majority of p53
Val135/WT mice developed tumors more rapidly than the wild-type mice and the tumors displayed more obvious histologic features of malignancy. Thus, at 9 months following the initial 4NQO treatment, f60% of the p53 Val135/WT mice had died, whereas <15% of the p53 WT/WT mice had died. In contrast, survival was >95% for control mice of either genotype. This implies that the mutant p53 allele 
4NQO-induced tumors in p53
Val135/WT mice. a and b, light photomicrographs of tongue SCC at Â40 and Â400 magnification from p53 Val135/WT mice, respectively; c and d, light photomicrographs of esophageal SCC at Â40 and Â400 magnification from p53
Val135/WT mice, respectively; e and f, light photomicrographs of forestomach SCC at Â40 and Â400 magnification from p53
Val135/WT mice, respectively. (23, 24) . Thus, loss of normal function of p53 leads to deregulation of the cell cycle and continued cell cycle progression after DNA damage resulting in accumulation of genetic damage. Our results strongly suggest that p53 plays a role in proliferation and apoptosis of squamous cells exposed to chemical carcinogens. Altered p53 protein expression has been associated with increased proliferative rates in other tumors, such as human breast cancer (25) . The observation in this study is the profound effect of the mutant p53 transgene on development of upper gastrointestinal SCC in p53 Val135/WT mice, strongly indicating that upper gastrointestinal SCC formation is highly p53 dependent.
Our findings are consistent with the results from Gallo et al. (26) in which they detected a germ-line p53 mutation in head and neck cancer patients with multiple malignancies and in their first-degree relatives. In addition, Rowley et al. (27) and Qin et al. (28) reported that the p53 gene is an early target for mutation in oral tumor development, with mutations being detected in 40% to 50% of premalignant lesions and SCCs. More recently, Ide et al. (29) found that p53 haploinsufficiency profoundly accelerates the onset of tongue tumors in mice lacking the xeroderma pigmentosum group A gene. All together, these results suggest that p53 plays a major and early role in head and neck tumor development. Our finding would seem to make this in situ mouse model particularly relevant for studying the role of p53 in head and neck tumorigenesis as well as for screening potential preventive or therapeutic agents for head and neck cancer.
To profile genes or pathways responsible for enhanced susceptibility to SCC in the oral cavity on 4NQO induction as well as the more rapid tumor growth and progression, altered gene expression in tongue tumors and normal tissues was investigated. Microarray studies with the GenMAPP analysis revealed that germ-line p53 mutation affects several cellular processes involved in the tumorigenesis possibly through the interplay among apoptosis, cell cycle arrest, transforming growth factorh signaling pathway, and Ras-mitogen-activated protein kinase pathway. For example, our data showed that wild-type p53 expression levels in both normal and tumor tissues were significantly decreased in p53
Val135/WT mice, which regulate multiple cell type -dependent intracellular and cellular events. Thus, cross-talk of these cellular processes may be involved in the tumorigenic process itself. Furthermore, microarray results showed that cell proliferation significantly increased, whereas apoptosis activity decreased in p53
Val135/WT samples compared with that from p53 WT/WT mice. On exposure p53 Val135/WT mice to 4NQO, the wild-type p53 could not function properly because of the dominant-negative effect of the mutant transgene, resulting in higher cell proliferation and decreased apoptosis relative to p53
WT/WT mice. In p53 WT/WT mice, high levels of wild-type p53 protein were induced, resulting in cell cycle arrest that should subsequently allow cells to recover from damage or undergo apoptosis. These results suggested that reduction of p53-dependent cell cycle inhibition and apoptosis might contribute to the observed increase in upper gastrointestinal tumor incidence in p53 Val135/WT mice. In summary, the present study and our previous in vivo studies have shown that in situ tumors with a germ-line p53 mutation can be induced in a variety of organ sites, including lung, uterus, colon, and upper gastrointestinal system (9) (10) (11) (12) . Microarray analyses began to offer clues for the mechanisms of tumor development associated with inactivation of p53. Our findings show that the combined use of mice with a dominant-negative p53 mutation combined with the carcinogen 4NQO yields a model of SCC of the upper gastrointestinal tract system that seems relevant to human oral SCC.
Materials and Methods
Agent
The chemical carcinogen 4NQO (Sigma Chemical Co., St. Louis, MO) was dissolved in propylene glycol to a final concentration of 5 mg/mL. The solution was stored at 4jC and a fresh aliquot was used each application session. p53 Genotype p53 Val135/WT mice were developed by microinjection of FVB/J mouse oocytes with a BALB/c mouse genomic clone of the p53 gene containing a point mutation in codon 135 (Ala-toVal) at exon 5. The mutation, a C-to-T transition, created a RFLP with a new HphI restriction enzyme cleavage site (recognition site: GGTGA). This mutation was used to genotype p53
Val135/WT mice using PCR-RFLP method as described previously (9) .
Tumor Development
Six-week-old p53 Val135/WT mice were randomized into four groups according to the p53 genotypes (Table 1) . Mice in groups 3 and 4 were lightly anesthetized by inhalation of methoxyflurane vapor. The palate was stroked once from the soft palate to the incisive papilla with a no. 3 camel hairbrush, which had been dipped once in 4NQO solution. Mice in groups 1 and 2 were given vehicle control (propylene glycol). All mice were treated by direct application thrice weekly for 16 weeks. Thirty-two weeks after the last treatment with 4NQO, animals from all four groups were euthanized by CO 2 asphyxiation. A portion of the upper gastrointestinal tumors and normal tissues were isolated, placed in individual tubes, and immediately frozen in liquid nitrogen. The remaining tumors and normal tissues were fixed in 10% neutral-buffered formalin overnight followed by 70% ethanol and paraffin embedding. Tissue sections (5 Am) were stained with H&E for histopathologic evaluation. A gross necropsy was done.
RNA Isolation and Amplification
Total RNA from each sample was isolated by Trizol (Invitrogen, Carlsbad, CA) and purified using the RNeasy Mini kit and RNase-free DNase Set (Qiagen, Valencia, CA) according to the manufacturer's protocols. In vitro transcription-based RNA amplification was then done on each sample. cDNA for each sample was synthesized using a SuperScript cDNA Synthesis kit (Invitrogen, Carlsbad, CA) and a T7-(dT) 24 primer: 5 ¶-GGCCAGTGAATTGTAATACGACTCACTA-TAGGGAGGCGG-(dT) 24 -3 ¶. The cDNA was cleaned using phase-lock gel (Fisher, Hampton, NH) phenol/chloroform extraction. Then, the biotin-labeled cRNA was transcribed in vitro from cDNA using a BioArray High-Yield RNA Transcript Labeling kit (ENZO Biochem, New York, NY) and purified again using the RNeasy Mini kit. Affymetrix GeneChip Probe Array and Cluster The labeled cRNA was applied to the Affymetrix Mu74Av2 GeneChip (Affymetrix, Santa Clara, CA), which contains >12,000 genes and expressed sequence tags on one array according to the manufacturer's recommendations. Every gene or expressed sequence tag is represented by a probe set consisting of f16 probe pairs (oligonucleotides) of 25-mer oligonucleotides. One sequence of a probe pair represents the complementary strand of the target sequence, whereas the other has a 1-bp mismatch at the central base pair position. This mismatch sequence serves as an internal control for specificity of hybridization.
Four or five independent samples were collected for each group. Array normalization and gene expression estimates were obtained using Affymetrix Microarray Suite version 5.0 software.
The array mean intensities were scaled to 1,500. These estimates formed the basis for statistical testing. Differential expression was determined on the combined basis of statistical testing using Student's t test and based on a ratio with a cutoff of P < 0.05 and fold change z2 called positive for differential expression. For the selected genes, expression indices were transformed across samples to a N(0,1) distribution using a standard statistical Z-transform. These values were put into the GeneCluster program of Eisen et al. (30) and genes were clustered using average linkage and correlation dissimilarity.
Rassf1A Methylation Analysis
The methylation status of the Rassf1A promoter region was determined by chemical modification of genomic DNA with sodium bisulfite and MSP. Bisulfite treatment converts cytosine bases to uracil bases but has no effect on methylcytosine bases. Bisulfite-treated DNA was used as a template for the MSP reaction. Primers for unmethylated reaction were forward 5 ¶-GGTGTTGAAGTTGTGGTTTG-3 ¶ and reverse 5 ¶-TATTA-TACCCAAAACAATACAC-3 ¶. Primers for methylated reaction were forward 5 ¶-TTTTGCGGTTTCGTTCGTTC-3 ¶ and reverse 5 ¶-CCCGAAACGTACTACTATAAC-3 ¶. The reaction was incubated at 95jC for 1 minute, 55jC for 1 minute, and 72jC for 1 minute for 35 cycles. The methylation fragment was 213 bp, and the nonmethylation fragment was 204 bp. DNA from normal skin was used as a control for unmethylated Rassf1A, and normal skin DNA treated with SssI methyltransferases was used as a control for methylated Rassf1A. H 2 O was used as negative control. Each PCR (25 AL) was loaded onto a 6% nondenaturing polyacrylamide gel, stained with ethidium bromide, and pictured under UV light.
GenMAPP
Signal transduction pathways, metabolic pathways, and other functional groupings of genes were evaluated for differential regulation using the visualization tool GenMAPP (University of California at San Francisco; http://www.genmapp.org). GenMAPP is a recently reported tool for visualizing expression data in the context of biological pathways (31) . We imported the statistical results of our data set into the program and used GenMAPP to illustrate pathways containing differentially expressed genes. Differential gene expression was based on p53 genotype status (P < 0.05; fold change >1.5).
Statistical Analysis
Fisher's exact test was used to determine the difference in incidence between p53
Val135/WT and p53 WT/WT mice. Nonparametric Wilcoxon's rank-sum test was used to determine the difference in tumor multiplicity between p53
Val135/WT and p53 WT/WT mice.
